Picture of Jubilant Pharmova logo

JUBLPHARMA — Jubilant Pharmova News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Jubilant Life Posts Lower Profit, Says Increased Remdesivir Output Capacity

Nov 4 (Reuters) - Jubilant Life Sciences Ltd  JULS.NS :
    * SEPT-QUARTER CONSOL NET PROFIT 2.24 BILLION RUPEES VERSUS
PROFIT
2.49 BILLION RUPEES YEAR AGO
    * CONSENSUS FORECAST FOR SEPT-QUARTER CONSOL NET PROFIT WAS
1.93
BILLION RUPEES -- REFINITIV DATA
    * SEPT-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 23.75
BILLION
RUPEES VERSUS 22.66 BILLION RUPEES YEAR AGO
    * ALLERGY BUSINESS AT PRE-COVID LEVEL DURING Q2’FY21
    * WITH GRADUAL OPENING OF US MARKETS, DEMAND CONDITIONS HAVE
BEGUN
IMPROVING
    * CONTINUE TO SEE NEW OPPORTUNITIES IN CDMO, GENERICS,
SPECIALTY
PHARMA
    * COVID-19 NOT LIKELY TO HAVE MATERIAL IMPACT ON PERFORMANCE
DURING FY21
    * SEE STRONG PHARMA, LSI AND DDDS PERFORMANCE IN H2
    * FOR LSI, SEE DOUBLE DIGIT REVENUE GROWTH, SIGNIFICANT
GROWTH IN
EBIDTA FOR FY21
    * REMDESIVIR PRODUCTION CAPACITY INCREASED FROM 200,000
VIALS TO
480,000 VIALS PER MONTH
    * LAUNCHED REMDESIVIR IN MULTIPLE NATIONS, FILED DOSSIERS IN
'SEVERAL OTHERS'

Source text for Eikon:  ID:nBSE70L1sd 
Further company coverage:  JULS.NS 

 ((bangalore.newsroom@thomsonreuters.com;))

Recent news on Jubilant Pharmova

See all news